Percutaneous Coronary Intervention (PCI)

Percutaneous coronary intervention (PCI) is a catheter-based procedure used to treat obstructive coronary artery disease by mechanically dilating stenotic or occluded coronary arteries, most commonly with balloon angioplasty followed by stent implantation.^[1] PCI is the most common revascularization procedure in the United States and is performed more than twice as often as coronary artery bypass grafting (CABG), with over 900,000 procedures annually.^[1]

The procedure encompasses balloon angioplasty, bare-metal stent (BMS) implantation, drug-eluting stent (DES) implantation, drug-coated balloon (DCB) angioplasty, atherectomy, and thrombectomy.^[1][3] Current-generation DES are the default stent type for PCI regardless of clinical presentation, lesion subtype, or comorbidities.^[3]

PCI is performed to treat coronary artery disease caused by atherosclerotic plaque accumulation in the epicardial coronary arteries.^[1][2] The procedure addresses flow-limiting stenoses that cause myocardial ischemia.

Risk factors for coronary artery disease and adverse PCI outcomes include:

• Patient factors: Diabetes mellitus, chronic kidney disease, advanced age, female sex (higher bleeding risk), acute coronary syndrome presentation^[3][4][5]
• Angiographic factors: Lesion length >20 mm, vessel diameter <3 mm, chronic total occlusion, bifurcation lesions, severe calcification, thrombotic lesions^[3][4]
• Procedural factors: Stent underexpansion, stent fracture, geographic miss, multiple stent layers, suboptimal initial PCI result^[4]

Lesion complexity is graded using the SYNTAX score, which independently predicts long-term major adverse cardiac and cerebrovascular events (MACCE) and death in patients treated with PCI.^[3]

Mechanism of balloon angioplasty: Balloon inflation stretches the artery and displaces atherosclerotic plaque away from the lumen, enlarging the entire vessel. Owing to inelastic elements in the plaque, stretching results in small localized dissections that can protrude into the lumen and serve as a nidus for acute thrombus formation.^[1]

Role of stents: Stents are wire meshes that, when expanded, provide a permanent scaffold that holds dissection flaps against the vessel wall, prevents elastic recoil, and reduces acute closure. Stent placement provides a larger acute luminal area than balloon angioplasty alone, reducing subsequent restenosis.^[1]

Mechanism of restenosis:

• Within 1 year: Restenosis is primarily due to neointimal hyperplasia — excessive smooth muscle cell proliferation and extracellular matrix deposition over the stent.^[1][4]
• After 1 year: Very late stent failure is more likely due to neoatherosclerosis — lipid-laden macrophage accumulation with necrotic core formation within the stented segment.^[1][4]

Drug-eluting stents: DES elute antiproliferative drugs (sirolimus, paclitaxel, everolimus, biolimus, zotarolimus) over 1–3 months or longer, inhibiting neointimal hyperplasia and reducing clinical restenosis by 50%.^[1]

Patients undergoing PCI present with a spectrum of coronary artery disease presentations:

• Stable angina: Predictable chest discomfort precipitated by exertion and relieved by rest or nitroglycerin; caused by stable atherosclerotic narrowing.^[2]
• Unstable angina: Angina at rest or with minimal exertion, new-onset severe angina, or crescendo angina; no detectable myocardial injury (normal troponin).^[6]
• NSTEMI: Ischemic symptoms with elevated high-sensitivity cardiac troponin (≥14 ng/L or dynamic change ≥20%); ECG may show ST depression or T-wave inversion.^[6]
• STEMI: Ischemic symptoms with new ST elevation at the J-point in at least 2 contiguous leads (≥2.5 mm in men <40, ≥2 mm in men ≥40, ≥1.5 mm in women for V2–V3); ST depression in V1–3 suggests posterior occlusion.^[6]
• Silent ischemia: Objective evidence of ischemia without symptoms, often in patients with diabetes or prior MI.^[2]

Physical examination in patients undergoing PCI may be normal or reveal signs of underlying heart disease:

• Hemodynamic status: Tachycardia, hypotension, or signs of cardiogenic shock in acute presentations^[6]
• Heart failure signs: Jugular venous distension, pulmonary crackles, peripheral edema, S3 gallop^[6]
• Vascular exam: Diminished or delayed femoral pulses (coarctation), pulse deficits (aortic dissection), bruits (peripheral artery disease)^[2]
• Cardiac auscultation: New murmurs (mitral regurgitation from papillary muscle dysfunction, ventricular septal defect)^[6]
• Signs of complications: Pericardial friction rub (pericarditis), muffled heart sounds with hypotension (tamponade)^[4]

There are no physical examination findings that are specific or diagnostic for coronary stenosis itself; examination focuses on identifying complications, comorbidities, and hemodynamic stability.^[3][6]

Initial assessment:

• 12-lead ECG within 10 minutes of presentation; repeat at least every 30 minutes if initial ECG non-diagnostic^[6]
• High-sensitivity cardiac troponin (hs-cTn) at presentation and serial measurements; hs-cTn T ≥14 ng/L or dynamic change ≥20% suggests myocardial injury^[6]
• Bedside echocardiography for LV function and complications^[6]

Coronary angiography: Gold standard for defining coronary anatomy and lesion severity. Visually estimated diameter stenosis ≥70% (non-left main) or ≥50% (left main) defines significant stenosis.^[3]

Physiologic assessment:

• FFR/iFR: Recommended for intermediate stenoses (40–69% diameter stenosis) to guide revascularization decisions. FFR ≤0.80 or iFR ≤0.89 indicates hemodynamically significant lesion; deferral is safe if FFR >0.80 or iFR >0.89.^[3][5]

Intravascular imaging:

• IVUS: Useful for procedural guidance in left main or complex coronary stenting to reduce ischemic events; minimum lumen area cutoffs for left main disease (≈6 mm², or 4.5–4.8 mm² in Asian patients)^[3]
• OCT: Reasonable alternative to IVUS for procedural guidance except in ostial left main disease; superior for detecting neoatherosclerosis, uncovered struts, and malapposition in stent failure^[3][4]

Risk stratification: SYNTAX score for anatomic complexity; STS score for surgical risk; validated risk scores for bleeding (PRECISE-DAPT, DAPT, PARIS)^[3][5]

Pre-procedural preparation:

• Aspirin 325 mg orally before procedure (if not contraindicated)^[1][6]
• P2Y12 inhibitor loading: clopidogrel 600 mg, prasugrel 60 mg, or ticagrelor 180 mg; cangrelor IV for P2Y12-naïve patients^[3][6]
• Anticoagulation during procedure: unfractionated heparin, enoxaparin, or bivalirudin^[1][3]

Procedural technique:

• Arterial access via radial (preferred) or femoral artery^[1][3]
• Guiding catheter cannulates coronary ostium; guidewire crosses stenosis; balloon angioplasty followed by stent placement^[1]
• IVUS/OCT guidance for complex lesions, left main disease, or stent failure^[3][4]
• Radial access reduces bleeding, vascular complications, and mortality in ACS compared with femoral access^[3][5]

Post-procedural care:

• DAPT with aspirin plus P2Y12 inhibitor: 6 months for stable ischemic heart disease, 12 months for ACS^[3][5]
• High-intensity statin therapy targeting ≥50% LDL-C reduction^[5]
• Cardiac rehabilitation referral for all eligible patients^[5]

ICU admission is indicated for patients undergoing PCI who develop:

• Cardiogenic shock complicating acute MI^[3][6]
• Hemodynamic instability requiring vasopressor or mechanical circulatory support^[3]
• Life-threatening ventricular arrhythmias (ventricular fibrillation, polymorphic ventricular tachycardia)^[3]
• Mechanical complications of MI (ventricular septal rupture, papillary muscle rupture, free wall rupture)^[6]
• Respiratory failure requiring mechanical ventilation^[6]
• Periprocedural cardiac arrest^[6]

Patients with uncomplicated PCI for stable angina or low-risk ACS can be managed on a telemetry ward or step-down unit.^[3][5]

Patients can be discharged same day or following day after uncomplicated PCI.^[1]

Discharge criteria include:

• Hemodynamic stability without vasopressor support^[3]
• No recurrent chest pain or ECG changes^[6]
• Adequate access site hemostasis^[1]
• No contrast-induced nephropathy or metabolic complications^[3]
• Ability to take oral medications, including DAPT^[3]
• Stable or improving renal function^[3]

Before discharge, patients should receive:

• Prescription for DAPT and high-intensity statin^[3][5]
• Cardiac rehabilitation referral^[5]
• Smoking cessation counseling if applicable^[5]
• Education on medication adherence and warning signs^[5]
• Transthoracic echocardiogram to assess LV function if not already performed^[6]

Acute procedural complications:

• Death: 0.1–0.3% for elective cases^[1]
• Myocardial infarction: <3% (large MI); most are small and detected by troponin rise^[1]
• Stroke: 0.1–0.4%^[1]
• Coronary dissection, perforation, or acute closure^[1][4]
• Vascular access complications: bleeding, hematoma, pseudoaneurysm, arteriovenous fistula^[3]
• Contrast-induced acute kidney injury^[3][5]

Late complications:

• Restenosis: Occurs in 20–50% (balloon angioplasty), 10–30% (BMS), 5–15% (DES) within first year; presents as recurrent angina or ACS^[1]
• Stent thrombosis: 1–3% incidence; acute (1 year); associated with death in 10–20% and MI in 30–70%^[1][4]
• Neoatherosclerosis: Lipid-laden plaque within stent, typically after 1 year; may cause very late stent failure^[1][4]

Risk factors for stent thrombosis: Premature DAPT discontinuation (3–9 fold increased risk in first month), stent underexpansion, malapposition, uncovered struts, calcified nodule, edge dissection, long stent length.^[4]

If restenosis does not occur, the long-term outcome after PCI is excellent.^[1]

Drug-eluting stents have been shown to reduce clinical restenosis by 50%, so that in uncomplicated lesions, symptomatic restenosis occurs in 5–10% of patients.^[1] Current-generation DES can reduce restenosis to <5%.^[2]

Factors associated with improved outcomes:

• Radial access (reduces mortality and bleeding in ACS)^[3]
• IVUS-guided stenting (reduces stent thrombosis, restenosis, and repeat revascularization)^[4]
• Complete revascularization^[3]
• Adherence to DAPT^[3]
• Second-generation DES (lower rates of late and very late stent thrombosis compared with first-generation DES)^[3]

Factors associated with worse outcomes:

• Diabetes mellitus^[4]
• Chronic kidney disease^[3]
• Reduced LV ejection fraction^[3]
• Complex coronary anatomy (high SYNTAX score)^[3]
• ACS presentation^[3]
• Incomplete revascularization^[3]

Critical care costs in the United States are substantial, and PCI is one of the most commonly performed procedures.^[1][5]

Cost-related considerations:

• DES are more expensive than BMS but reduce restenosis and repeat revascularization, making them cost-effective for most patients.^[3]
• Generic formulations of statins are cost-saving for secondary prevention.^[5]
• The use of radial access may reduce costs by decreasing bleeding and vascular complications.^[3]
• High out-of-pocket costs for P2Y12 inhibitors and newer antiplatelet agents can impede adherence; clinicians should discuss costs with patients.^[5]
• Recent declines in PCSK9 inhibitor prices have improved cost-effectiveness for very high-risk patients.^[5]

Post-PCI follow-up:

• Clinical follow-up at least annually to assess symptoms, functional status, medication adherence, and complications^[5]
• DAPT duration: 6 months for SIHD, 12 months for ACS; may be shortened (12 months) based on ischemic and bleeding risk^[3][5]
• Lipid monitoring 4–12 weeks after statin initiation or dose adjustment, then every 3–12 months^[5]
• Blood pressure management targeting <130/80 mm Hg^[5]
• Diabetes management with SGLT2 inhibitors or GLP-1 receptor agonists if indicated^[5]
• Cardiac rehabilitation participation to improve outcomes^[5]
• Routine periodic stress testing is not recommended in asymptomatic patients without change in clinical status^[5]

Key PCI Trials:

• SYNTAX (2009): Compared PCI with paclitaxel-eluting stent to CABG in 1800 patients with three-vessel or left main disease. At 5 years, MACE and cardiac mortality were significantly higher with PCI in patients with high-complexity disease (SYNTAX score >33). Repeat revascularization was significantly higher with PCI (13.5 vs 5.9% at 1 year), while stroke was higher with CABG (2.2 vs 0.6%).^[1][3][5]
• FREEDOM (2012): Randomized 1900 patients with diabetes and multivessel disease to CABG or PCI. At 5 years, all-cause mortality was higher with PCI (16.3 vs 10.9%); MI was higher with PCI (13.9 vs 6.0%); stroke was lower with PCI (2.4 vs 5.2%). CABG is preferred for diabetics with multivessel disease.^[3][5]
• ISCHEMIA (2020): Randomized 5179 patients with stable CAD and moderate-severe ischemia to invasive vs. conservative strategy. No difference in the primary composite endpoint of cardiovascular death or MI at 3.3 years. Invasive strategy improved angina-related quality of life in symptomatic patients.^[5]
• COMPLETE (2019): Randomized 4041 STEMI patients with multivessel disease to staged PCI of non-infarct arteries vs. culprit-only PCI. Staged PCI reduced the combined endpoint of death or MI at 3 years.^[3][5]
• CULPRIT-SHOCK (2017): In patients with AMI and cardiogenic shock, culprit-lesion-only PCI with possible staged revascularization reduced 30-day risk of death or severe renal failure compared with immediate multivessel PCI. Culprit-lesion-only PCI is the default strategy in cardiogenic shock.^[3][5]
• FAME (2009): FFR-guided PCI reduced adverse events by 30% compared with angiography-guided PCI when revascularization was restricted to hemodynamically significant lesions (FFR ≤0.80).^[3][5]
• ISAR-DESIRE 3 (2013): Compared DCB, paclitaxel-eluting stent, and plain balloon for DES-ISR. DCB and DES both reduced need for repeat revascularization compared with plain balloon; DES was superior to DCB for late lumen loss.^[4][7]
• RIBS IV (2015): Randomized 309 patients with DES-ISR to DEB or EES. EES provided superior late angiographic and clinical results compared with DEB.^[4][8]
• PEPCAD II (2009): Paclitaxel-coated balloon vs. paclitaxel-eluting stent for BMS-ISR. At 3 years, DCB maintained superiority for target lesion revascularization (6.2% vs. 15.4%).^[9]
• SIRIUS (2004): Sirolimus-eluting stent vs. bare metal stent in 1058 patients. At 12 months, target lesion revascularization was 4.9% vs. 20% (P<0.001), with a 70–80% reduction in clinical restenosis in high-risk subsets.^[10]